Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Rucaparib is licensed as a single-agent in the US Patients using Olaparib, benefited for a long period of time.
Rucaparib is licensed as a single-agent in the US Patients using Olaparib, benefited for a long period of time
